Division of Nephrology, Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
Department of Internal Medicine III, University Hospital Carl Gustav Carus at the Technische Universität Dresden, Dresden, Germany.
J Pathol. 2019 Apr;247(5):697-707. doi: 10.1002/path.5248. Epub 2019 Feb 25.
Necrosis of a cell is defined by the loss of its plasma membrane integrity. Morphologically, necrosis occurs in several forms such as coagulative necrosis, colliquative necrosis, caseating necrosis, fibrinoid necrosis, and others. Biochemically, necrosis was demonstrated to represent a number of genetically determined signalling pathways. These include (i) kinase-mediated necroptosis, which depends on receptor interacting protein kinase 3 (RIPK3)-mediated phosphorylation of the pseudokinase mixed lineage kinase domain like (MLKL); (ii) gasdermin-mediated necrosis downstream of inflammasomes, also referred to as pyroptosis; and (iii) an iron-catalysed mechanism of highly specific lipid peroxidation named ferroptosis. Given the molecular understanding of the nature of these pathways, specific antibodies may allow direct detection of regulated necrosis and correlation with morphological features. Necroptosis can be specifically detected by immunohistochemistry and immunofluorescence employing antibodies to phosphorylated MLKL. Likewise, it is possible to generate cleavage-specific antibodies against epitopes in gasdermin protein family members. In ferroptosis, however, specific detection requires quantification of oxidative lipids by mass spectrometry (oxylipidomics). Together with classical cell death markers, such as TUNEL staining and detection of cleaved caspase-3 in apoptotic cells, the extension of the arsenal of necrosis markers will allow pathological detection of specific molecular pathways rather than isolated morphological descriptions. These novel pieces of information will be extraordinarily helpful for clinicians as inhibitors of necroptosis (necrostatins), ferroptosis (ferrostatins), and inflammasomes have emerged in clinical trials. Anatomical pathologists should embrace these novel ancillary tests and the concepts behind them and test their impact on diagnostic precision, prognostication, and the prediction of response to the upcoming anti-necrotic therapies. Copyright © 2019 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
细胞坏死定义为其质膜完整性的丧失。形态上,坏死以几种形式发生,如凝固性坏死、液化性坏死、干酪样坏死、纤维蛋白样坏死等。从生物化学角度来看,坏死被证明代表了许多遗传决定的信号通路。这些途径包括:(i) 激酶介导的坏死性凋亡,其依赖于受体相互作用蛋白激酶 3(RIPK3)介导的假激酶混合谱系激酶结构域样(MLKL)磷酸化;(ii) 炎性体下游的 Gasdermin 介导的坏死,也称为细胞焦亡;以及 (iii) 一种名为铁催化的高度特异性脂质过氧化的机制,称为铁死亡。鉴于对这些途径性质的分子理解,特定的抗体可能允许直接检测受调控的坏死并与形态特征相关联。坏死性凋亡可以通过免疫组织化学和免疫荧光染色,使用针对磷酸化 MLKL 的抗体来特异性检测。同样,可以针对 Gasdermin 蛋白家族成员的表位生成切割特异性抗体。然而,在铁死亡中,特定的检测需要通过质谱(脂质组学)来定量氧化脂质。与经典的细胞死亡标志物(如 TUNEL 染色和凋亡细胞中 cleaved caspase-3 的检测)一起,坏死标志物的扩展将允许对特定分子途径进行病理检测,而不是孤立的形态描述。这些新的信息对于临床医生来说将非常有帮助,因为坏死性凋亡(坏死抑制剂)、铁死亡(铁死亡抑制剂)和炎性体已在临床试验中出现。解剖病理学家应该接受这些新的辅助检测和背后的概念,并测试它们对诊断精度、预后和对即将到来的抗坏死治疗反应的预测的影响。版权所有 © 2019 英国和爱尔兰大不列颠病理学会。由 John Wiley & Sons,Ltd. 出版。